Drug/Small Molecule:
fluvastatin

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

Links to Unannotated Labels

These links are to labels associated with fluvastatin that have not been annotated by PharmGKB.

  1. DailyMed - DrugLabel PA166105138

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA APOE E2 N/A N/A N/A
No VIP available CA No VIP available APOE E3 N/A N/A N/A
No VIP available CA No VIP available APOE E4 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *1 N/A N/A N/A
VIP No VIP available VA CYP2C9 *2 N/A N/A N/A
VIP No VIP available VA CYP2C9 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *4 N/A N/A N/A
No VIP available CA VA SLCO1B1 *1A N/A N/A N/A
No VIP available CA VA SLCO1B1 *14 N/A N/A N/A
rs1057910 1075A>C, 47545517A>C, 47639A>C, 96741053A>C, CYP2C9*3, CYP2C9*3:Ile359Leu, CYP2C9: I359L, CYP2C9:359Ile>Leu, CYP2C9:Ile359Leu, Ile359Leu, mRNA 11A>C
A > C
Missense
Ile359Leu
No VIP available CA VA
rs11045819 14089937C>A, 21329813C>A, 463C>A, 50686C>A, Pro155Thr, SLCO1B1:*4, SLCO1B1:463C>A
C > A
Missense
Pro155Thr
No VIP available No Clinical Annotations available VA
rs12487736 2392G>A, 47399679C>T, 47459679C>T, Val798Ile
C > T
Missense
Val798Ile
rs17238540 2298+117T>G, 2457+117T>G, 25249857T>G, 27506T>G, 74655498T>G, HMGCR:SNP 29
T > G
Intronic
No VIP available CA VA
rs17244841 14863A>T, 25237214A>T, 451-174A>T, 74642855A>T, HMGCR:SNP 12
A > T
Intronic
No VIP available CA VA
rs1799752 16457_16458insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 2306-119_2306-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 26840042_26840043insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 61565890_61565891insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, ACE D/I
- > ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC
Intronic
rs1799853 430C>T, 47506511C>T, 8633C>T, 96702047C>T, Arg144Cys, CYP2C9*2, CYP2C9:144Arg>Cys, CYP2C9:Arg144Cys, mRNA 455C>T
C > T
Missense
Arg144Cys
No VIP available No Clinical Annotations available VA
rs1800588 -557C>T, 29514232C>T, 4501C>T, 58723675C>T
C > T
5' Flanking
No VIP available CA VA
rs1922242 173898T>A, 2065-76T>A, 25206510A>T, 87173667A>T
A > T
Intronic
No VIP available CA VA
rs2231142 13600044G>T, 32689C>A, 421C>A, 89052323G>T, ABCG2: Q141K, ABCG2:421C>A, ABCG2:Q141K, ABCG2:c.421C>A, Gln141Lys, rs2231142
G > T
Missense
Gln141Lys
VIP No Clinical Annotations available No Variant Annotations available
rs3846662 1564-106A>G, 1722+45A>G, 23092A>G, 25245443A>G, 74651084A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs4149056 14091673T>C, 21331549T>C, 521T>C, 52422T>C, SLCO1B1*5, Val174Ala
T > C
Missense
Val174Ala
No VIP available No Clinical Annotations available VA
rs4331 14619A>G, 2193A>G, 26838204A>G, 471A>G, 61564052A>G, Ala157=, Ala731=
A > G
Synonymous
Ala157Ala
No VIP available No Clinical Annotations available VA
rs4341 16557G>C, 2306-19G>C, 26840142G>C, 584-19G>C, 61565990G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs4693075 18900C>G, 779-1022C>G, 84192168G>C, 8739889G>C
G > C
Intronic
No VIP available CA VA
rs4783961 -998G>A, 10609093G>A, 4060G>A, 56994894G>A
G > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs4986910 1331T>C, 1334 C allele, 1334T>C, 28285T>C, 37391367A>G, 445Thr allele, 99358524A>G, CYP3A4*3, CYP3A4:M445T, Met444Thr, Met445Thr, mRNA 1438T>C
A > G
Missense
Met445Thr
No VIP available CA VA
rs5882 10630291G>A, 1264G>A, 25258G>A, 57016092G>A, CETP:I405V, CETP:Ile405Val, CETP:rs5882 A>G
G > A
Missense
Val422Ile
No VIP available No Clinical Annotations available VA
rs5925 11230881T>C, 1455T>C, 1578T>C, 1596T>C, 1836T>C, 1959T>C, 2493683T>C, 35825T>C, Val485=, Val526=, Val532=, Val612=, Val653=
T > C
Synonymous
Val526Val
No VIP available CA VA
rs60282872 -34delG, 17343539delC, 17740165delC, 5161delG, NC_000017.10:g.17740165delC, NM_001005291.2:c.-34delG, NM_004176.4:c.-34delG, del abolished ApaI restriction site
C > -
5' UTR
No VIP available No Clinical Annotations available VA
rs776746 12083G>A, 219-237G>A, 321-1G>A, 37303382C>T, 581-237G>A, 689-1G>A, 99270539C>T, CYP3A5*1, CYP3A5*3, CYP3A5*3C, CYP3A5:6986A>G, g.6986A>G, intron 3 splicing defect, rs776746 A>G
C > T
Acceptor
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • Fluindostatin
  • Fluvastatina [INN-Spanish]
  • Fluvastatine [INN-French]
  • Fluvastatinum [INN-Latin]
  • fluvastatin sodium
Trade Names
  • Canef
  • Cranoc
  • Lescol
  • Lescol XL
Brand Mixture Names

PharmGKB Accession Id:
PA449688

Description

Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

Source: Drug Bank

Indication

To be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart disease (CHD) to reduce the risk of requiring coronary revascularization procedures, for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with CHD, and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Fluvastatin selectively and competitively inhibits the hepatic enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. Inhibition results in a decrease in hepatic cholesterol levels which stimulates the synthesis of LDL receptors and increases hepatic uptake of LDL cholesterol. The end result is decreased levels of plasma total and LDL cholesterol.

Source: Drug Bank

Pharmacology

Fluvastatin, the first synthetically-derived HMG-CoA reductase inhibitor, is a hydrophilic, acidic, antilipemic agent used to lower cholesterol and triglyceride levels associated with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb), to slow the progression of coronary atherosclerosis in patients with CHD and as secondary prevention therapy in patients with CHD to reduce the risk of requiring coronary revascularization procedures. Although similar to lovastatin, simvastatin, and pravastatin, fluvastatin has a shorter half-life, no active metabolites, extensive protein binding, and minimal CSF penetration. Fluvastatin acts primarily in the liver. It is prepared as a racemate of two erythro enantiomers of which the 3R,5S enantiomer exerts the pharmacologic effect.

Source: Drug Bank

Food Interaction

May be taken with or without food, but should be taken consistently.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Undergoes hepatic metabolism primarily via hydroxylation of the indole ring at the 5- and 6-positions to 5-hydroxy fluvastatin and 6-hydroxy fluvastatin, respectively. N-dealkylation to N-desisopropyl fluvastatin and beta-oxidation of the side chain also occurs. Metabolized primarily by the CYP2C9 isozyme system (75%), and to a lesser extent by CYP3A4 (~20%) and CYP2C8 (~5%). Hydroxylated metabolites retain some pharmcological activity, but are present as conjugates (glucuronides and sulfates) in the blood and are rapidly eliminated via bile into feces.

Source: Drug Bank

Protein Binding

98% bound to plasma proteins

Source: Drug Bank

Absorption

Rapidly and almost completely absorbed (> 90%), but undergoes extensive first pass metabolism. Bioavailability is 24% (range 9-50%).

Source: Drug Bank

Half-Life

1-3 hours

Source: Drug Bank

Toxicity

Generally well-tolerated. May cause GI upset (diarrhea, nausea, constipation, gas, abdominal pain), myotoxicity (mypothy, myositis, rhabdomyolysis), and hepatotoxicity.

Source: Drug Bank

Route of Elimination

Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). No significant (<6%) renal excretion of fluvastatin occurs in humans.

Source: Drug Bank

Volume of Distribution

  • 0.35 L/kg

Source: Drug Bank

Chemical Properties

Chemical Formula

C24H26FNO4

Source: Drug Bank

Isomeric SMILES

CC(C)n1c2ccccc2c(c1/C=C/[C@@H](C[C@@H](CC(=O)O)O)O)c3ccc(cc3)F

Source: OpenEye

Canonical SMILES

CC(C)N1C(\C=C\[C@H](O)C[C@H]

Source: Drug Bank

Average Molecular Weight

411.4659

Source: Drug Bank

Monoisotopic Molecular Weight

411.18458653

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Fluvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
HMGCR (source: Drug Bank)

Drug Interactions

Drug Description
fluvastatin Increased/decreased effect according to spacing (source: Drug Bank)
fluvastatin Increased/decreased effect according to spacing (source: Drug Bank)
fluvastatin Increased risk of rhabdomyolysis with this combination (source: Drug Bank)
fluvastatin Increased risk of rhabdomyolysis with this combination (source: Drug Bank)
fluvastatin Increased/decreased effect according to spacing (source: Drug Bank)
fluvastatin Increased/decreased effect according to spacing (source: Drug Bank)
fluvastatin Possible myopathy and rhabdomyolysis (source: Drug Bank)
fluvastatin Possible myopathy and rhabdomyolysis (source: Drug Bank)
fluvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fluvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fluvastatin Increases the effect and toxicity of fluvastatin (source: Drug Bank)
fluvastatin Increases the effect and toxicity of fluvastatin (source: Drug Bank)
acenocoumarol The statin increases the anticoagulant effect (source: Drug Bank)
acenocoumarol The statin increases the anticoagulant effect (source: Drug Bank)
anisindione The statin increases the anticoagulant effect (source: Drug Bank)
bezafibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
bezafibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
cholestyramine Increased/decreased effect according to spacing (source: Drug Bank)
cholestyramine Increased/decreased effect according to spacing (source: Drug Bank)
colchicine Increased risk of rhabdomyolysis with this combination (source: Drug Bank)
colchicine Increased risk of rhabdomyolysis with this combination (source: Drug Bank)
colestipol Increased/decreased effect according to spacing (source: Drug Bank)
colestipol Increased/decreased effect according to spacing (source: Drug Bank)
cyclosporine Possible myopathy and rhabdomyolysis (source: Drug Bank)
cyclosporine Possible myopathy and rhabdomyolysis (source: Drug Bank)
dicumarol The statin increases the anticoagulant effect (source: Drug Bank)
dicumarol The statin increases the anticoagulant effect (source: Drug Bank)
fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fluconazole Fluconazole increases the effect and toxicity of fluvastatin (source: Drug Bank)
fluconazole Fluconazole increases the effect and toxicity of fluvastatin (source: Drug Bank)
gemfibrozil Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
gemfibrozil Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
rifabutin The rifamycin decreases the effect of statin drug (source: Drug Bank)
rifabutin The rifamycin decreases the effect of statin drug (source: Drug Bank)
rifampin The rifamycin decreases the effect of statin drug (source: Drug Bank)
rifampin The rifamycin decreases the effect of statin drug (source: Drug Bank)
warfarin The statin increases the anticoagulant effect (source: Drug Bank)
warfarin The statin increases the anticoagulant effect (source: Drug Bank)
fluvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fluvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fluvastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
fluvastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
fluvastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)
fluvastatin The rifamycin decreases the effect of the statin drug (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to fluvastatin: 40

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof of Concept Study Using the Clinical Practice Research Datalink (CPRD). Clinical pharmacology and therapeutics. 2013. Carr Daniel F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: methotrexate pathway. Pharmacogenetics and genomics. 2011. Mikkelsen Torben S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB: very important pharmacogene--HMGCR. Pharmacogenetics and genomics. 2011. Medina Marisa Wong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cytochrome P450 2C9-CYP2C9. Pharmacogenetics and genomics. 2010. Van Booven Derek, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women. Journal of lipid research. 2010. Hamrefors Viktor, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. Pharmacogenomics. 2010. Chien Kuo-Liong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transporter pharmacogenetics and statin toxicity. Clinical pharmacology and therapeutics. 2010. Niemi M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clinical pharmacology and therapeutics. 2009. Anthony M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pharmacogenetics of statin therapy: when the body aches, the mind will follow. Journal of the American College of Cardiology. 2009. Rossi Joseph S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics. 2009. Willrich Maria Alice Vieira, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics. 2009. Keskitalo Jenni E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenetics and genomics. 2008. Donnelly Louise A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis. 2008. Polisecki Eliana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics. 2008. Couvert Philippe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Machine learning methods and docking for predicting human pregnane X receptor activation. Chemical research in toxicology. 2008. Khandelwal Akash, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Hagenbuch B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 2008. Krauss Ronald M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenetics and genomics. 2008. Pasanen Marja K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of lipid research. 2007. Singer Jonathan B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line. Journal of cardiovascular pharmacology. 2007. Bertrand-Thiebault Céline, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacological research : the official journal of the Italian Pharmacological Society. 2007. Zuccaro Piergiorgio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clinical pharmacology and therapeutics. 2006. Niemi Mikko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle & nerve. 2006. Vladutiu Georgirene D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical pharmacology and therapeutics. 2006. Neuvonen Pertti J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis. 2006. Bercovich Dani, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Clinical consequences of cytochrome P450 2C9 polymorphisms. Clinical pharmacology and therapeutics. 2005. Kirchheiner Julia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: a relation with the -786T>C polymorphism. Pharmacogenetics and genomics. 2005. Abe Koji, et al. PubMed
An association study of 43 SNPs in 16 candidate genes with atorvastatin response. The pharmacogenomics journal. 2005. Thompson J F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA : the journal of the American Medical Association. 2004. Chasman Daniel I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics. 2004. Kivistö Kari T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clinical pharmacology and therapeutics. 2003. Kirchheiner Julia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. Journal of molecular medicine (Berlin, Germany). 2002. Salek Lorraine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circulation research. 2001. Lutucuta S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacokinetics of fluvastatin. Clinical pharmacokinetics. 2001. Scripture C D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharmaceutics & drug disposition. 2000. Cohen L H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. Journal of the American College of Cardiology. 2000. Marian A J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. Journal of clinical pharmacology. 1999. Meadowcroft A M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug metabolism and disposition: the biological fate of chemicals. 1999. Fischer V, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0078-0176-05
DrugBank:
DB01095
ChEBI:
5136
KEGG Compound:
C07014
PubChem Compound:
1548972
PubChem Substance:
206649
46505668
Drugs Product Database (DPD):
2250527
ChemSpider:
1265982
Therapeutic Targets Database:
DAP000554
FDA Drug Label at DailyMed:
8a1823e7-26fb-4858-bac7-9e152e5ea16a

Clinical Trials

These are trials that mention fluvastatin and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.